Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome.
In order to investigate a possible common role of central dopaminergic mechanisms in the release of PRL and LH in patients with the polycystic ovary syndrome (PCO), plasma LH pulsatile profiles and the response to GnRH were studied in a group of 12 PCO patients before and after 3 months of treatment with bromocriptine, 2.5 mg twice daily. They were divided into two groups of six patients according to the occurrence or not of hyperprolactinemia (plasma PRL, 30.3 +/- 2.7 (SE) ng/ml vs. 9.5 +/- 0.8 (SE) ng/ml). Integrated LH secretion significantly decreased in hyperprolactinemic [2537 +/- 371 (SE) vs. 907 +/- 102 mIU/ml X min] as well as in normoprolactinemic (2847 +/- 460 vs. 901 +/- 152 mIU/ml X min) patients, but there was no difference in the response of the two groups. The LH increment after a bolus injection of 100 micrograms GnRH was reduced (P less than 0.01) to the same extent in both groups. These results indicate a dopaminergic component in the control of LH release in PCO patients, independent of the mechanism governing PRL secretion. Since bromocriptine reduced LH secretion, it may be useful for the management of this condition.
D001971:Bromocriptine / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood
D007987:Gonadotropin-Releasing Hormone; D001971:Bromocriptine; D011388:Prolactin; D007986:Luteinizing Hormone